INTERVIEW: Oxford Biodynamics Presenting in Washington Summit

Oxford Biodynamics Plc (LON:OBD) CSO Dr Alexandre Akoulitchev talks to DirectorsTalk about presenting its work in Washington at the Summit on Emerging Immunotherapies for Hematologic Diseases. Alexandre describes for us the field of immunotherapies, what it is that OBD brings to the field, its expertise in patient stratifications in immunotherapies applications, explains how relevant the earlier studies are to new immunotherpy applications and the advantages EpiSwitch technology been demonstrating in its latest applications.

Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    What is EpiSwitch and how is it used?

    Grounded in Epigenetics Oxford BioDynamics’ EpiSwitch technology is based on epigenetics: mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune diseases, neurologic

    Oxford BioDynamics

    FDA publishes guidance to help in developing new ALS therapies

    After gathering input from patients, researchers, and advocates, the U.S Food and Drug Administration (FDA) has released new guidance on the development of therapies for amyotrophic lateral sclerosis (ALS). Among its recommendations, it is advising more communication with

    Oxford BioDynamics

    Qualtrax Boosts Oxford BioDynamics Efficiencies

    Businesses involved in areas such as the pharmaceutical sector must demonstrate the highest levels of compliance, traceability and quality. Given the large volumes of documents generated by such organisations, important tasks such as keeping track of

    Oxford BioDynamics

    What you need to know about rheumatoid arthritis

    Rheumatoid arthritis (RA) is a chronic disease that affects the joints throughout your body. It often starts in the hands and feet RA is an autoimmune disease, it happens when your immune system attacks your own cells. While

    Oxford BioDynamics

    Want to Slow Down Your ALS? Try Smiling!

    What does smiling have to do with ALS? Or happiness, contentment, or feeling positive? These expressions of our sense of well-being are important to those of us living with ALS. According to a study of 224 ALS patients, participants

    Oxford BioDynamics

    How does alcohol affect rheumatoid arthritis?

    Drinking alcohol in moderation is typically safe for people with rheumatoid arthritis (RA). According to the Arthritis Foundation, drinking alcohol in moderation is usually safe, and may even reduce certain types of inflammation. Some research says that small

    Oxford BioDynamics

    Ice Bucket Challenge Creator Continues To Inspire

    A Westchester man battling ALS is fighting for a cure and one way he hopes to do that is by bringing back the ice bucket challenge. Pat Quinn was diagnosed with the deadly degenerative disease in

    Oxford BioDynamics

    MND Association welcomes report on benefits and terminal illness

    A report revealing terminally ill people face devastating and far-reaching financial hardship because of a ‘made-up policy fudge’ has been welcomed by the Motor Neurone Disease (MND) Association. The All Party Parliamentary Group for Terminal Illness

    Oxford BioDynamics

    Having this temperature in your joints must NOT be ignored

    Arthritis is a type of inflammatory autoimmune disease and is a musculoskeletal condition which is caused by the body’s joints. The areas most commonly affected include the hands, fingers, hips, knees and spine. The disease commonly affects